



alfapump[®] DSR – Potential breakthrough treatment for volume overload in heart failure

Sequana Medical has leveraged its alfapump experience and is developing alfapump DSR (Direct Sodium Removal), a fully implanted system to manage volume overload in heart failure (HF) patients by removing excess sodium and fluid from the body.

Volume overload in heart failure is a major clinical problem and the leading cause of hospitalisations for patients with heart failure




DSR therapy is Sequana Medical’s proprietary therapy to remove excess sodium and fluid from the body




DSR therapy involves the use of the peritoneal cavity for the removal of sodium via diffusion from the body into a sodium-free solution (DSR infusate)

Studies have demonstrated that DSR therapy is capable of removing large quantities of sodium and fluid in a safe, tolerable and consistent manner

Pre-clinical study in 5 healthy pigs and 10 pigs with simulated heart failure (HF)




First-in-human single dose DSR cross-over study in 10 patients with peritoneal dialysis (PD)



alfapump DSR leverages on proven elements: DSR, alfapump and implanted port

- 1 Administration of DSR infusate to peritoneal cavity
- 2 Sodium from body diffuses into DSR infusate
- 3 alfapump moves sodium-rich fluid into the bladder
- 4 Body eliminates excess fluid via urination



First-in-human repeated dose **alfapump** DSR study expected to start in H2 2019

Sources: 1: Costanzo et al., J. Am. Coll., 2007; 2: Kilgore et al., 2017; 3: Ross et al., 2010; 4: Testani, Circ Heart Failure, 2014 & 2016

Important Regulatory Disclaimer: DSR therapy is still in development and any statement regarding safety and efficacy arise from pre-clinical studies and ongoing clinical investigations which have yet to be completed.